Abstract: Frovatriptan succinate substantially in an amorphous form is disclosed. Also disclosed is a composition comprising frovatriptan succinate in a solid form, wherein at least about 80% by weight of the solid is frovatriptan succinate in an amorphous form. The present invention also provides a process for preparing frovatriptan succinate substantially in an amorphous form by providing a solution of frovatriptan succinate in one or more solvents capable of dissolving the frovatriptan succinate and substantially removing the solvent from the solution.

Abstract: An improved process for the preparation of pyrimidine derivatives is provided comprising reacting a Wittig reagent of the general formula wherein R is an alkyl of from 1 to 10 carbon atoms, aryl or arylalkyl, R1 is a substituted or unsubstituted hydrocarbon group, R2 and R3 are the same or different and are hydrogen or a substituted or unsubstituted hydrocarbon group; Z is sulfur, oxygen, sulfonyl, or imino which may be substituted by formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, amino substituted by sulfonyl or alkylsulfonyl, and sulfonyl substituted by alkyl, amino or alkylamino and X is a halogen; with an aldehyde of the general formula wherein R4 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt and each R5 are the same or different and are hydrogen or a hydrolyzable protecting group, or each R5, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R5 is bonded to the

Abstract: Pharmaceutical compositions containing ezetimibe or its pharmaceutically acceptable salt that is substantially free of microcrystalline cellulose or crystalline cellulose are disclosed. Also disclosed are pharmaceutical compositions containing micronized particles of ezetimibe.

Abstract: A process for preparing perindopril is provided comprising condensing an N-[(S)-1-carbethoxybutyl]-(S)-alanyl halide of formula II: wherein X is a halide with an (2S,3aS,7aS)-2-carboxyperhydroindole of formula III: wherein R is hydrogen or a protecting group.

Abstract: Ropinirole hydrochloride substantially free of impurities and a process for its preparation is provided. Also provided is ropinirole base substantially in polymorph Form A and a process for its preparation. Pharmaceutical compositions containing the same are also provided.

Abstract: The present invention provides a novel intermediate of ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate or a pharmaceutically acceptable salt thereof and a process for its preparation. The present invention also provides for the preparation of ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate of Formula I or a pharmaceutically acceptable salt thereof using the intermediate.

Abstract: A sustained release pharmaceutical composition in solid dosage form is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical agents; (b) a first high viscosity release retarding cellulose ether; and (c) a second high viscosity release retarding cellulose ether, wherein the first and second high viscosity release retarding cellulose ethers are of the same material.

Abstract: Novel polymorph Forms III and V of desloratadine are provided. Pharmaceutical compositions containing such polymorphs are also provided.

Abstract: Crystalline forms of almotriptan and almotriptan malate are disclosed. Processes for their preparation and pharmaceutical compositions containing the same are also disclosed.

Abstract: Mifepristone substantially in polymorph form M is provided. Also provided is a process for the preparation of polymorph form M of mifepristone comprising the steps of (a) dissolving crude mifepristone in a polar solvent at an elevated temperature to obtain a clear solution; (b) cooling the solution to a temperature and for a time period sufficient to form a precipitate of mifepristone crystals; and (c) isolating the precipitate of mifepristone crystals to obtain the polymorph form M of mifepristone.

Abstract: A process for purifying olmesartan medoxomil is provided comprising (a) dissolving olmesartan medoxomil in a solvent system comprising a ketone and at least one solvent selected from the group consisting of an alcohol-containing solvent, an ester-containing solvent and mixtures thereof to obtain a solution; and (b) recovering substantially pure olmesartan medoxomil. Also disclosed is substantially pure olmesartan medoxomil and pharmaceutical compositions containing same.

Abstract: Rizatriptan benzoate in an amorphous form is disclosed. Also disclosed is a process for preparing rizatriptan benzoate substantially in amorphous form comprising the steps of (a) preparing a solvent solution comprising non-amorphous rizatriptan benzoate and one or more solvents capable of dissolving the non-amorphous rizatriptan benzoate; and (b) recovering the amorphous form of rizatriptan benzoate from the solution.

Abstract: A process for preparing neutral esomeprazole in an amorphous form is provided comprising (a) providing an aqueous solution comprising a salt of esomeprazole; (b) neutralizing the solution with a neutralization agent to provide a neutralized solution; (c) contacting the neutralized solution with an extracting solvent; and (d) recovering the neutral esomeprazole in an amorphous form.

Abstract: A process for the preparation of (2S, 3aS, 7aS)perhydroindole-2-carboxylic acid is provided comprising (a) esterifying a cis-perhydroindole-2-carboxylic acid with a first alcohol of the formula ROH and a suitable free acid to provide the acid salt (AS) of Formula V: (b) reacting the acid salt of Formula V with a first base to provide a compound of Formula VI: (c) treating the product of step (b) with an L-tartaric containing acid in a second alcohol of the formula ROH to precipitate a compound of Formula VII: (d) reacting the compound of Formula VII with a second base to provide a compound of Formula II (e) hydrolyzing the compound of Formula II to provide the (2S, 3aS, 7aS)perhydroindole-2-carboxylic acid.

Abstract: A process for preparing a crystalline form of linezolid is provided comprising (a) providing a solution comprising linezolid in an organic solvent having a boiling point of less than or equal to about 150° C.; (b) adding an anti-solvent having a boiling point greater than or equal to about 50° C. to the solution; and (c) recovering the crystalline form of linezolid.

Abstract: A process for the preparation of a novel crystalline polymorph of olmesartan medoxomil, designated Form G, is provided comprising the steps of (a) preparing a solution comprising olmesartan medoxomil and one or more solvents selected from the group consisting of a nitrile, alcohol and mixtures thereof at a suitable temperature to obtain a solution; and (b) recovering olmesartan medoxomil substantially in polymorph Form G from the solution. A novel polymorph Form G of olmesartan medoxomil and pharmaceutical compositions containing same are also provided herein.

Abstract: A process for preparing perindopril is provided comprising condensing an N-[(S)-1-carbethoxybutyl]-(S)-alanyl halide of formula II: wherein X is a halide with an (2S,3aS,7aS)-2-carboxyperhydroindole of formula III: wherein R is hydrogen or a protecting group.

Abstract: A process for the preparation of a biphenyl-containing compound of general formula I: wherein R1 is a C3-6 carbonyl containing compound; R2 is a substituted or unsubstituted, straight or branched C3-6 alkyl group, or R1 and R2 together with the nitrogen atom to which they are bonded are joined together to form a substituted heterocyclic group selected from the group consisting of substituted or unsubstituted imidazoles, substituted or unsubstituted benzimidazoles and substituted or unsubstituted 1,3-diazaspiro[4,4]non-1-en-4-one; and R3 is a carboxylic acid ester, cyano, a substituted or unsubstituted 1H-tetrazolyl group or a substituted or unsubstituted group which may be converted in vivo into a carboxy group is provided, the process comprising reacting a compound of general formula II: wherein R1 and R2 have the aforestated meanings with a compound of general formula III: wherein Z is a leaving group and R3 has the aforestated meaning in a biphasic solvent system in the presence of a phase tra

Abstract: A process for the preparation of anastrozole is provided, the process comprising: (a) reacting 3,5-bis(1-cyano-1-methylethyl)benzyl halide with a 4-Z-1,2,4-triazole compound of the formula wherein Z is a protecting group to produce 2,2?-[5-(4-Z-1,2,4-triazolium-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile) halide; and (b) deprotecting the 2,2?-[5-(4-Z-1,2,4-triazolium-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile)halide to produce anastrozole. Also provided is anastrozole substantially free of its isomers.

Abstract: A process for preparing Form II crystals of clarithromycin is provided comprising (a) treating clarithromycin with a carboxylic acid in an organic solvent to provide a clarithromycin acid salt; and, (b) heating the clarithromycin acid salt at a temperature capable of providing Form II crystals of clarithromycin.